Cogent Biosciences
COGT
39 hedge funds and large institutions have $33.7M invested in Cogent Biosciences in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 18 reducing their positions, and 17 closing their positions.
4.6% less ownership
Funds ownership: 47.3% → 42.7% (-4.6%)
26% less funds holding
Funds holding: 53 → 39 (-14)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
61% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 18
70% less capital inflows, than outflows
Capital inflows: $2.1M | Capital outflows: $6.98M
71% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.07M |
| 2 |
Paloma Partners
Greenwich,
Connecticut
|
+$288K |
| 3 |
Barclays
London,
United Kingdom
|
+$175K |
| 4 |
Jane Street
New York
|
+$167K |
| 5 |
Goldman Sachs
New York
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$946K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$517K |
| 4 |
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$299K |
| 5 |
Bank of New York Mellon
New York
|
-$232K |
COGT Hedge Fund Activity: Q2 2019 in Review
39 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2019, worth a combined $33.7M — down 46% from $62.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of COGT and 5 opened new positions — a net loss of 12 holders — while 18 trimmed existing stakes and 7 added.
The largest buyer was Millennium Management, adding an estimated $1.07M. The largest seller was BlackRock, cutting an estimated $2.8M.
- 39 institutional investors held Cogent Biosciences (COGT) as of Q2 2019, down from 53 in Q1 2019.
- Funds reported $33.7M of Cogent Biosciences stock for Q2 2019, down 46% quarter-over-quarter.
- 5 funds opened new Cogent Biosciences positions in Q2 2019 and 17 closed out, a net change of -12 holders.
- The largest Cogent Biosciences buyer in Q2 2019 was Millennium Management, an estimated $1.07M added.
- The largest Cogent Biosciences seller in Q2 2019 was BlackRock, an estimated $2.8M sold.
Based on aggregated 13F filings for Q2 2019.